Physician profile

Stephen Brown

Psychiatry · Los Angeles, CA

NPI 1487811568

$650.79

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$111.49
Food and Beverage$81.07

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Teva Pharmaceuticals USA, INC. $284.33 2021-2024
Indivior INC. $120.43 2019-2023 Perseris
Sunovion Pharmaceuticals INC. $98.18 2019
Alkermes, INC. $70.39 2019
Janssen Pharmaceuticals, INC $35.51 2019
Neurocrine Biosciences, INC. $24.03 2019
Lundbeck LLC $17.92 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephen Brown

$650.79

in general payments reported 2019-2025

Years
2019-2024
Top company
Teva Pharmaceuticals USA, INC.

https://glasscript.com/doctor/158550/stephen-brown

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.